Precigen (NASDAQ:PGEN) Announces Quarterly Earnings Results, Beats Expectations By $0.02 EPS

by · The Cerbat Gem

Precigen (NASDAQ:PGEN – Get Free Report) released its quarterly earnings results on Wednesday. The biotechnology company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.02, Zacks reports. Precigen had a negative net margin of 3,521.68% and a negative return on equity of 123.06%.

Precigen Stock Performance

Precigen stock traded up $0.12 during trading hours on Wednesday, reaching $1.79. 1,382,664 shares of the stock were exchanged, compared to its average volume of 1,174,087. The stock has a market cap of $524.24 million, a P/E ratio of -3.25 and a beta of 1.58. Precigen has a 52-week low of $0.65 and a 52-week high of $2.17. The firm’s 50 day moving average is $1.57 and its 200 day moving average is $1.14.

Analyst Ratings Changes

PGEN has been the subject of several research reports. JMP Securities reiterated a “market outperform” rating and issued a $5.00 price target on shares of Precigen in a research report on Tuesday, January 14th. HC Wainwright reiterated a “buy” rating and issued a $6.00 price target (up previously from $4.00) on shares of Precigen in a research report on Thursday, January 23rd. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Precigen has a consensus rating of “Hold” and a consensus target price of $7.00.

Check Out Our Latest Analysis on Precigen

About Precigen

(Get Free Report)

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.

Read More